|Videos|June 2, 2022
Treatment Approaches for Good Risk Patients with Renal Cell Carcinoma
Author(s)Tom Powles, MBBS, MRCP, MD, Brian Shimkus, MD
A discussion on how patient risk groups play into deciding on the appropriate treatment for renal cell carcinoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
A bispecific in biliary tract cancer, dostarlimab organ preservation in rectal cancer, and KRAS G12D data in pancreatic cancer stood out at ESMO 2026.
The European Commission approved adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease based on DESTINY-Breast05 data.
Dirk Schadendorf, MD, reviewed final STARBOARD data for encorafenib, binimetinib, and pembrolizumab in first-line BRAF V600–mutant melanoma.
In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
Matthew Lee, MD, discusses the first clinical data for BG-C477, a CEACAM5-targeting ADC, in advanced NSCLC.
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
In a phase 3 trial, the Breast Cancer Locator was noninferior to wire localization and lowered positive margin rates in nonpalpable breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC
2
Prior Regimen Did Not Affect Daraxonrasib Benefit in Pretreated Pancreatic Cancer
3
Sacituzumab Govitecan PFS Benefit Holds Across Subgroups in Untreated mTNBC
4
Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?
5